# HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors

> **NCT05102214** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Henlius Biotech** · enrollment: 150 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumors
- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** HLX301

## Key facts

- **NCT ID:** NCT05102214
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-03
- **Primary completion:** 2023-09-15
- **Final completion:** 2024-02
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05102214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05102214, "HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05102214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*